Clinical Trials · NCT01377246

Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency

CompletedPhase 3Octreotide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Mario Negri Institute for Pharmacological Research
Enrollment
100
Start date
May 2011
Locations
6 sites, Italy
Primary endpoint
Total kidney volume (TKV) change (delta TKV) as assessed by spiral computed tomography (spiral CT) scan.
View Octreotide compound reference